Although the multiplicity in transport proteins assessed during drug development is continuously increasing, the clinical relevance of the breast cancer resistance protein (BCRP) is still under debate. Here, our aim is to rationalize the need to consider BCRP substrate and inhibitor interactions and to define optimum selection and acceptance criteria between cell-based and vesicle-based assays in vitro. Information on the preclinical and clinical pharmacokinetics (PK), drug-drug interactions, and pharmacogenomics data was collated for 13 marketed drugs whose PK is reportedly associated with BCRP interaction. Clinical examples where BCRP impacts drug PK and efficacy appear to be rare and confounded by interactions with other transporters. Thirty-seven compounds were selected to be tested as BCRP substrates in a cell-based assay using MDCKII cells (Madin-Darby canine kidney cells) and 18 in membrane vesicles. Depending on the physicochemical compound properties, we observed both in vitro systems to give false-negative readouts. In addition, the inhibition potential of 19 compounds against BCRP was assessed in vesicles and in MDCKII cells, where we observed significant system and substrate-dependent IC 50 values. Therefore, neither of the two test systems is superior to the other. Instead, one system may offer advantages under certain situations (e.g., low permeability) and thus should be selected based on the physicochemical compound properties. Finally, given the clinical relevance of BCRP, we propose that its evaluation should remain issue-driven: for low permeable, low bioavailable drugs, in particular when other more common processes do not allow a mechanistic understanding of any unexpected absorption or brain disposition, and for drugs with a low therapeutic window.
Introduction
The breast cancer resistance protein (BCRP, previously MXR, mitoxantrone resistance-associated protein) was discovered in multidrug-resistant cancer cells, with the identification of chemotherapeutic agents as substrates. BCRP has a ubiquitous tissue distribution; thus, similar to multidrug resistance protein 1 (MDR1), its physiologic role is to protect the body by limiting intestinal absorption and exposure of vital organs to xenobiotics (Polgar et al., 2008) . Clinical examples have been reported where interindividual differences in BCRP function correlated with increased toxicity (gefitinib-induced diarrhea) or altered pharmacokinetics (PK) (rosuvastatin, sulfasalazine, and topotecan) (Giacomini et al., 2010) (Table 1) .
Sulfasalazine is a low permeable compound described as a BCRP substrate in vitro (Urquhart et al., 2008) (Table 1) . After oral administration to Bcrp knockout mice, a striking 111-fold increase in area under the curve (AUC) was observed when compared with wildtype mice (Zaher et al., 2006) . However, several clinical studies have demonstrated that sulfasalazine PK in humans is not as sensitive to BCRP efflux and has a large interindividual variability in its PK. Thus, its potential use as a BCRP probe substrate in the clinic is controversial (Adkison et al., 2010) . Rosuvastatin, a BCRP substrate in vitro, has an estimated bioavailability of around 10-20%. Metabolism only plays a minor role in rosuvastatin elimination, as it is excreted mainly unchanged in bile (Table 1) . Several clinical studies showed an impact of BCRP polymorphisms on its PK and pharmacodynamics (PD) . The rise in exposure may be owing to the overlapping effects of increased oral bioavailability and decreased hepatic clearance (Ieiri et al., 2009 ). In clinical drug-drug interaction (DDI) studies, eltrombopag, ritonavir, or cyclosporine A (CsA) increased rosuvastatin plasma exposure by up to 7-fold, but these perpetrators are also strong organic aniontransporting polypeptide (OATP) inhibitors, a significant distribution and elimination pathway of rosuvastatin.
The Food and Drug Administration (FDA; http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm292362.pdf) and European Medicines Agency (EMA; http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ (Zaher et al., 2006) c.34GG and c.421AA/CC/CA: ,2-to 4-fold AUC increases; inconsistent findings between studies (Adkison et al., 2010; Schnepf and Zolk, 2013) No significant association with PK (+dual MDR1/ BCRP inhibitor: pantoprazole) (Adkison et al., 2010) ; 3.2 max fold AUC increase (+BCRP and enzymes inhibitor: curcumin) (Kusuhara et al., 2012) OATP2B1 substrate (Kusuhara et al., 2012 (Kitamura et al., 2008) c.421CA/AA: 2-to 2.4-fold AUC increases (Zhang et al.,. 2006 ; Ieiri et al., 2009; Keskitalo et al., 2009b) 1.6 max fold AUC increase (+ dual OATP/BCRP inhibitors: eltrombopag, ritonavir) (Allred et al., 2011) ; 7-fold increase (+multiple transporters and enzymes inhibitor: CsA) (Schnepf and Zolk, 2013) (Mizuno et al., 2012) ; no impact on plasma exposure but on brain distribution (Tang et al., 2012; Schnepf and Zolk, 2013) c.421CA/AA 1.7-to 3-fold AUC increase (Mizuno et al., 2012) (Yamagata et al., 2007) c.421CA: increase in F from ;30% to ;40%, no significant change in AUC, very small sample size (Sparreboom et al., 2005) Increase in F from ;40% to ;100% (+dual MDR1 / BCRP inhibitor: elacridar) (Schnepf and Zolk, 2013) F;40% (Gelderblom et al., 2003) Not extensively metabolized (Schnepf and Zolk, 2013) ADME, absorption, distribution, metabolism, and elimination; CL, clearance; F, apparent oral bioavailability in humans; NR, not reported; Y, substrate (yes).
a From Benet et al., (1996) and http://www.druginteractioninfo.org if not stated otherwise.
b
Low:
,30 nm/s; medium: 30-100 nm/s; high:
.100 nm/s.
c: Data from L-MDR1 cells in the presence of inhibitor (Poirier et al., 2014) .
2010/05/WC500090112.pdf) guidelines recommend evaluating all investigational drugs in vitro to determine whether they are potential substrates of MDR1 and/or BCRP. Both agencies recognize, however, that drugs with high permeability and high solubility tend to be well absorbed even if substrates of active transport, and therefore can be exempt from in vivo evaluation of MDR1 or BCRP interactions (as victim). Both regulatory agencies also require the evaluation of new molecules as BCRP inhibitors. The rationale for this requirement is limited, and is thought to be largely due to the similarities with MDR1. A recent review of the effect of BCRP on human PK concluded that examples from human studies are rare and confounded by the functional redundancy of BCRP with other transporters such as MDR1 (e.g., topotecan), organic anion transporters (OATs; e.g., methotrexate), or OATPs (e.g., rosuvastatin) (Schnepf and Zolk, 2013) (Table 1) . When assessing BCRP substrate or inhibition properties, different in vitro systems are used to study efflux transporters: systems overexpressing BCRP, such as transfected cell lines or membrane vesicles, and organotypic cell lines such as Caco-2 (Zamek- Gliszczynski et al., 2013) . Different test systems may have limitations, depending on the type of study conducted. For instance, membrane vesicular assays may give false-negative results for highly lipophilic compounds due to high nonspecific binding (Xia et al., 2005; Giacomini et al., 2010) . Likewise, polarized transcellular assays are not suitable for low permeable compounds, since they do not sufficiently penetrate the cells and therefore do not reach the export protein, potentially resulting in false-negative results. The existence of multiple binding sites on transport proteins could also add to the complexity of identifying substrate and inhibitor molecules in in vitro assay systems, leading to incorrect interpretation (Muenster et al., 2008; Giri et al., 2009) . Careful selection of substrates and inhibitors is therefore critical for designing definitive studies, and may circumvent the current issues with very high experimental interlaboratory variability in in vitro assays .
The first objective of this paper was to define criteria that necessitate a need to assess BCRP substrate and inhibition in drug development. Although regulatory agencies and the International Transporter Consortium continuously increase the number of transport proteins to be assessed during drug development, there is still debate on the clinical relevance of BCRP (Tweedie et al., 2013) . In this regard, preclinical and clinical evidence for the clinical relevance of BCRP will be discussed.
The second objective of this work was to define the optimum choice of in vitro test system for BCRP assessment. Using in-house experimental conditions, we directly compare results between vesicle-based and cell-based assays for BCRP substrate and inhibition, with the goal to identify which of these two assays is best suited under which circumstances.
Material and Methods
Compounds used in the in vitro experiments were of a typical purity of $98% and were obtained from Sigma-Aldrich (Buchs, Switzerland), Fluka (Buchs, Switzerland), or Apin Chemicals (Abingdon, Oxfordshire, UK). The BCRP vesicles were from Solvo Biotechnology (Szeged, Hungary).
Cell Origin and Culture
The parent LLC-PK1 cell line is a porcine kidney epithelial cell line (Lewis lung cancer porcine kidney 1). The parent MDCKII cell line is a canine kidney epithelial cell line (Madin-Darby canine kidney). LLC-PK1, MDCKII, L-MDR1 (LLC-PK1 cells transfected with human MDR1), and M-BCRP (MDCKII cells transfected with human BCRP) cell lines were obtained from Dr. A. Schinkel, The Netherlands Cancer Institute (Amsterdam, The Netherlands), and were used under a license agreement. Control and BCRPexpressing membrane vesicles derived from transfected Sf9 cells were obtained from Solvo Biotechnology (Budapest, Hungary).
MDCKII and M-BCRP cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin. L-MDR1 cells were grown in M-199 medium with phenol red containing 10% fetal bovine serum and 100 units/ml penicillin and 100 mg/ml streptomycin. Cells were split every 3 or 4 days by trypsinization. All cells were cultivated at 37°C in a humidified 5% CO 2 cell culture incubator. Standard tissue culture flasks were from Corning (Corning B.V. Life Sciences, Amsterdam, The Netherlands) and 96-well plates were from Millipore (Billerica, MA). All cells were seeded on permeable inserts (0.11 cm 2 area, pore size 0.4 mm, low density; Millipore) and transport measurements were performed at day 3 after seeding.
Transcellular 96-Insert Plate Automated In Vitro Experiment
The method used has been reported previously (Poirier et al., 2014) . Tightness of the cell monolayer was controlled via the permeability of the extracellular marker lucifer yellow (10 mM). The assays were automated and performed on a robot (Tecan Freedom Evo 200 Base; Tecan, Männedorf, Switzerland) with integrated incubator (Liconic Storex Incubator; Liconic Instruments, Mauren, Liechtenstein). The medium was removed from apical (100 ml) and basolateral (240 ml) compartments and replaced on the receiver side by culture medium without phenol red, with or without inhibitor. The transcellular transport measurement was initiated by adding the test compound [final concentration 1 mM, except PhIP (2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine)] (2 mM) dissolved in culture medium together with the extracellular marker lucifer yellow to the donor side. The inhibitor (1 mM elacridar, 1 mM Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino [19,29:1,6] pyrido [3,4-b] indole-3-propanoic acid 1,1-dimethylethyl ester], or test compound) was added to both sides. The transport experiment was performed in both directions in triplicates. The plates containing the inserts were incubated at 37°C and 5% CO 2 under continuous shaking (100 rpm). Samples were taken from the donor and the opposite (acceptor) side after 3.5 hours of incubation. Concentrations of substrate in both compartments were determined by scintillation counting for radioactive compounds or by high-performance liquid chromatography with tandem mass spectrometry. The extracellular marker (lucifer yellow) was quantified using a Tecan Ultra Evolution Reader at 430/535 nm (Extension/Emission wavelengths). Triplicate inserts were used for each condition. Experiments showing lucifer yellow permeation superior to 1%/h were rejected. Digoxin (MDR1) or PhIP (BCRP) was included on each 96-insert plate as a positive control.
BCRP Vesicles 96-Filter Plate In Vitro Experiment
Buffers Preparation. The assay buffer [10 mM Hepes-Tris, 100 mM KNO 3 , 10 mM Mg(NO 3 ) 2 , 50 mM sucrose] and the wash buffer (10 mM Hepes-Tris, 100 mM KNO 3 , 50 mM sucrose) were filtered (through a sterile 0.2-mm filter for the assay buffer). On the day of the assay, a 200 mM MgAMP solution (250 mM Na 2 AMP and 1 M MgCl 2 ) was prepared as well as 12 mM MgATP, 12 mM MgAMP, and radiolabeled substrate solutions by diluting their respective stocks in assay buffer. The final concentrations of MgATP (or MgAMP) and radiolabeled substrate in each well during the assay were 4 mM and 1 mCi/ml, respectively. The amount of membrane vesicles in each well during the assay was 25 mg. The final volume dosed in each well was 75 ml, of which 25 ml was from either MgATP or MgAMP and 50 ml was from the assay buffer containing membrane vesicles and the radiolabeled substrate.
Preincubation. Membrane vesicles were thawed rapidly at 37°C and then placed on ice. Assay buffer (50 ml) containing membrane vesicles and radiolabeled substrate (final concentration 1 mM, except 2 mM methotrexate) was dispensed to a 96-well standard plate. Next, 50 ml of 12 mM MgATP (or MgAMP) without or with inhibitor was added to a second 96-well standard plate (MgATP/MgAMP plate). Both plates were incubated at 37°C for 5 minutes under shaking conditions. During this time the filtering apparatus (MultiScreen HTS vacuum manifold; Millipore) was set up. The 96-filter plate (MultiScreen HTS-FB, catalog #MSFBN6B50; Millipore) was wetted with 100 ml/well of wash buffer. The wetted filter plate was then dmd.aspetjournals.org incubated at room temperature for 1 minute. The wash buffer was then filtered under vacuum.
Incubation. Twenty-five microliters per well of the MgATP/MgAMP plate was added to corresponding wells of the membrane plate, thereby initiating the transport phase of the assay. The membrane plate was incubated at 37°C for 2 minutes under shaking conditions (400 rpm), and then 150 ml of ice-cold wash buffer was added to each well. The samples from each well were then transferred to the 96-filter plate. Samples were filtered under vacuum and washed five additional times with 200 ml/filter of wash buffer. The filtering apparatus was turned on after each addition of wash buffer and turned off when the filter went dry and before adding additional wash buffer. Once the wash phase ended, 5 ml of assay buffer containing membrane vesicles and radiolabeled substrate (start mix) was dispensed to three unused filters of the 96-filter plate. The bottom of the 96-filter plate was blotted gently with filter paper and dried with a hair dryer for several minutes. The collection plate was removed from the 96-filter plate and the bottom dried with a hair dryer for an additional 10-20 minutes, with care taken to not overheat the plastic part of the plate. The filters are considered dry when they turn from translucent to opaque. The cassette adapter (TopCount adapter for MultiScreen HTS white, catalog #MSTPCWH50; Millipore) was snapped onto the bottom of the 96-filter plate. One hundred microliters of MicroScint 20 scintillation cocktail (PerkinElmer, Shelton, CT) was added to each well. The top of the 96-filter plate was sealed with clear sealing tape (TopSeal-A: 96-well microplates; PerkinElmer). The plate was shaken for several minutes and radioactivity was counted using the TopCount NXT instrument from Perkin Elmer. The settings on the TopCount were as follows: 2 minutes/well for sample count.
Bioanalytics. Analytical standards were prepared during the sample incubation as part of the assay. At the end of the experiment, samples were quenched with 3 volumes of acetonitrile containing the internal standards. Analyses of nonlabeled compounds were performed by high-performance liquid chromatography with tandem mass spectrometry. In brief, fast reversephase liquid chromatography was conducted on a Shimadzu 10ADvp pump system (Shimadzu, Kyoto, Japan) coupled with a PAL HTS autosampler (CTC Analytics, Zwingen, Switzerland). The injection volume, mobile phase composition, analytical column, and gradient profile were optimized for each compound. Mass spectrometric detection was performed on an AB Sciex API4000 or QTrap4000 equipped with a TurboIonspray source (AB Sciex, Framingham, MA). Detection by tandem mass spectrometry was based on precursor ion transition to the strongest intensity product ion. Key instrumental conditions were optimized to yield best sensitivity. Typical run time was 1.5 minutes. The calibration range was typically 1 nM to 4 mM for each analyte. AB Sciex Analyst 1.4.2 software was used for data analysis. Concentration of compound in the samples was calculated from the peak area ratio between the analyte and the internal standard.
Data Evaluation
Transcellular Transport (Cell-Based Assay). For the transcellular transport, the following equation was used for data evaluation:
where P app , A, C 0 , and dQ/dt represent the apparent permeability, the filter surface area, the initial concentration, and the amount transported per time period, respectively. P app values were calculated on the basis of a single time point. Transport efflux ratios (ERs) were calculated as follows: ER ¼ P app BA P app AB where P app BA is the permeability value in the basolateral-to-apical direction, and P app AB is the permeability value in the apical-to-basolateral direction. The average passive permeability value, P app i, was calculated as follows:
where P app ABi and P app BAi represent the apparent permeability in the apicalto-basolateral and basolateral-to-apical directions, respectively, in the presence of inhibitor.
Vesicle-Based Assay. All tested conditions within an experiment were run in triplicate. The disintegrations per minute obtained from each filter were converted to picomoles per milligram of protein per minute as follows: pmol=mg protein=min ¼ ðdpmÞ Â ½substrate concentration ðmMÞ Â ½volumeðmlÞ ðtotal dpmÞ Â ðmg of membrane vesiclesÞ Â ½timeðminÞ
Substrate concentration refers to the radiolabeled plus unlabeled concentration of substrate added to each well, the volume refers to the total volume in each well during the transport assay (i.e., 75 ml), total dpm refers to the total disintegrations per minute added to each well at the start of the transport assay, mg of membrane vesicles refers to the amount of membrane vesicles added to each well (i.e., 25 mg), and time refers to the duration of the transport assay (i.e., 2 minutes). The net uptake for each condition was calculated using the mean value of the triplicate filters as follows: net uptake ðpmol=mg=minÞ ¼ triplicate mean ATP ðpmol=mg=minÞ 2 triplicate mean AMP ðpmol=mg=minÞ
The fold uptake for each condition was calculated using the mean value of the triplicate filters as follows: 
where X is either the ER for the cell-based assay or the net uptake for the vesiclebased assay, X max is the maximum value without inhibitor, X min is the value with Ko143 (maximum inhibition), [I] is the nominal inhibitor concentration in micro moles per liter, and s is the slope factor (or Hill coefficient). Origin v7 (OriginLab Corporation, Northampton, MA) was used to perform the nonlinear fitting of the data and evaluation of IC 50 and s parameters.
Cutoff Criteria. The cutoff criteria to categorize compounds as substrate or nonsubstrate for both the transcellular cell-based assay and the vesicle-based assay were refined based on the results (see Discussion) and previously published status (substrate/nonsubstrate).
BCRP Clinical Relevance: Literature Search
The data presented in Table 1 were gathered from recent reviews on BCRP, the American and European DDI regulations, the Metabolism and Transport Drug Interaction Database from the University of Washington, and the latest published material (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2010/05/WC500090112.pdf ; http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf; http:// www.druginteractioninfo.org; Poguntke et al., 2010; Meyer zu Schwabedissen and Kroemer, 2011; Schnepf and Zolk, 2013) . The selection of drugs was not intended to offer an exhaustive list, but rather aimed to represent a characteristic sample in terms of absorption, distribution, metabolism, and elimination properties; pharmaceutical class; and regulators' concerns. The parameters collected were absorption, distribution, metabolism, and elimination/PK properties (enzymes and transporter substrate properties, bioavailability, and any remarkable feature); passive permeability; BCRP substrate property in vitro; in vivo studies in Bcrp1 knockout mice; results of BCRP pharmacogenetic clinical studies; and finally, results of DDI interaction studies potentially linked to BCRP. Table 1 is an overview of drugs whose PK and/or PD has been reported to be linked to BCRP (for reviews, see Poguntke et al., 2010;  Meyer zu Schwabedissen and Kroemer, 2011; Schnepf and Zolk, 2013). The main drugs under scrutiny are statins and chemotherapy agents, such as tyrosine kinase inhibitors and camptothecins.
Results

BCRP Clinical Relevance
If the absorption, distribution, or elimination of a drug is solely or mainly dependent on one specific pathway, the risk for DDI increases and the specific underlying mechanism can be more easily identified. Therefore, to put the importance of BCRP in the selected clinical examples into context, information on the involvement of other pathways (drug-metabolizing enzymes and other transporters) is also described (Table 1) . Rosuvastatin, pitavastatin, pravastatin, and topotecan are mainly excreted unchanged, whereas the other drugs listed are metabolized via cytochrome P450 enzymes aldehyde oxidases (methotrexate), carboxylesterases (irinotecan), or bacterial azoreductases (sulfasalazine). All have been identified in vitro as substrates of BCRP, as well as MDR1, OATs, or OATPs (Table 1) .
The significance of transporters in vivo is related to drug permeability; the most significant impact of efflux transport activity is when drugs have a low bioavailability and low permeability (in terms of fold interaction) along with a narrow therapeutic index (in terms of safety) (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf; Giacomini et al., 2010; Schnepf and Zolk, 2013) . For highly permeable molecules, the transporter effect will be minimal. As detailed in Table 1 , all drugs listed have a reported low to medium permeability except for imatinib (highly permeable). Methotrexate, pitavastatin, gefitinib, and imatinib all have a bioavailability above 40%, whereas the bioavailability for the remaining drugs listed is below 40%.
All selected BCRP substrates, apart from gefitinib, showed increases in plasma exposure, brain distribution, and/or decreases in total or biliary clearance in Bcrp1 knockout mice (Table 1) . The strongest impact was on sulfasalazine, with a 111-fold increase in plasma AUC. However, in human genetically controlled studies, sulfasalazine PK was not as sensitive to BCRP efflux as that observed in mice, with only a 2-to 4-fold increase in AUC. Indeed, for most of the drugs listed, the PK changes observed in Bcrp knockout mice did not translate into similar effects in the clinic. One exception is rosuvastatin, which showed clinical AUC increases of between 2-and 4-fold in genetically controlled studies, and this is similar to the effects seen in Bcrp1 knockout mice (Table 1) . Other clinical studies reported impact on bioavailability (topotecan), PD (methotrexate), and toxicity (irinotecan). Imatinib, which is highly permeable with high bioavailability, was not impacted in Bcrp1 knockout mice or individuals with functional impairment of BCRP. Finally, apart from gefitinib, all drugs whose PK was altered in patients with certain BCRP singlenucleotide polymorphisms showed a bioavailability below 30%.
In contrast to MDR1-mediated clinical DDI studies, of which there are more than 60 cases reported, only four DDI studies have reported potential links to BCRP (Table 1 : methotrexate, sulfasalazine, rosuvastatin, and topotecan) (Poirier et al., 2014) . At the time of publication, we are not aware of any other clinical example. There were no reported changes in the PK of sulfasalazine when coadministered with pantoprazole, a known inhibitor of BCRP in vitro, and only a 3.2-fold increase in AUC when coadministered with high doses of curcumin. These findings are surprising, given the preclinical observations (111-fold change in AUC) and effect of BCRP polymorphism (up to 4-fold change in AUC) with sulfasalazine. For the other three drugs, changes in the PK parameters or toxicity were observed when coadministered with marketed drugs (omeprazole, pantoprazole, eltrombopag, ritonavir, and CsA) or probe inhibitors (elacridar). An important consideration is that the perpetrator drugs mentioned earlier are not pure inhibitors of BCRP, and are recognized inhibitors of multiple transport proteins and enzymes.
BCRP Substrate In Vitro Assay
Cell-Based Assay (M-BCRP). Thirty-seven compounds were selected to be tested as BCRP substrates in M-BCRP cells. Six compounds were selected as negative controls: CsA and ritonavir, previously reported as non-BCRP substrates (Gupta et al., 2004; Xia et al., 2007) ; propranolol, metoprolol, and verapamil, highly permeable drugs with no records as BCRP substrates; and metformin, a low permeability drug with questionable BCRP substrate data (Hemauer et al., 2010) . Propranolol, metoprolol, and verapamil showed ER in M-BCRP cells of around 1, which was insensitive to Ko143 and equivalent in MDCKII (parental cells); the same was observed for fumitremorgin C (FTC) ( Table 2 ). The ER of CsA and ritonavir in M-BCRP cells was higher than 2 but equivalent to the ER in MDCKII cells and also not sensitive to Ko143. Therefore, these two compounds were categorized as nonsubstrates.
Most of the other test compounds were selected as they have been identified previously as BCRP substrates (references given in Table 4 ) except FTC and MK571 [5-(3-(2-(7-Chloroquinolin-2-yl)ethenyl) phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid], which are so far described as inhibitors. Twenty compounds had a Ko143-sensitive ER above 2 in M-BCRP cells and markedly greater than the ER in MDCKII cells (Table 2 ). Daunorubicin and rifampicin ERs in M-BCRP cells were significantly above 2 and around 2 in MDCKII cells, which is characteristic of BCRP substrates. However, their ERs in M-BCRP cells were insensitive to Ko143. This can be due to differences in binding sites and substrate-dependent inhibition (Muenster et al., 2008; Giri et al., 2009) . Those examples well illustrate that not only the ER value in M-BCRP cells should be taken into consideration, but the impact of Ko143 and the ER in the control cells to avoid falsenegative or false-positive results (Fig. 1) .
Erythromycin also appears as a false negative in the cell-based assay. The ER of erythromycin in M-BCRP cells was above 2 (8.0) but insensitive to Ko143 (7.6) and equivalent in MDCKII cells (10.8; Table 2 ), pointing toward an involvement of the canine P-glycoprotein (P-gp) expressed in those cells. Janvilisri and coworkers (2005) identified erythromycin as a BCRP substrate working with cells in suspension (no transcellular transport assessment) with a 1-hour erythromycin preincubation. The difference in experimental conditions could explain the divergence in results; erythromycin appears here not to be a BCRP substrate.
For 10 of the compounds tested, all samples from the receiver compartments were below the limit of quantification, corresponding to a permeability of around 15 nm/s when using the limit of quantification as a nominal concentration. Thus, doxorubicin, estrone-3-sulfate (E3S), vincristine, lamivudine, methotrexate (MTX), rosuvastatin, metformin, tamoxifen, nitrofurantoin, and sulfasalazine appear not permeable in MDCKII cells, and therefore the transcellular cell-based assay is not a suitable method for testing these compounds for BCRP substrate interaction.
All confirmed BCRP substrates were also found to be MDR1 substrates, except simvastatin (Supplemental Table 1 ).
Vesicle-Based BCRP Assay. From the 37 compounds tested in M-BCRP cells, 18 were selected to be tested in membrane vesicles isolated from insect cells overexpressing human BCRP, based on their availability with a radiolabel.
The negative controls metoprolol, propranolol, and metformin all exhibited a fold uptake of 1.0, with an insignificant net uptake (Table 3 ). The fold uptake of verapamil was 1.3 with a net uptake of 15.1 pmol/mg/min; however, it was not affected by Ko143.
Fluvastatin, pitavastatin, MTX, topotecan, rosuvastatin, and E3S all showed a fold uptake higher than 2 with high net uptake that was dmd.aspetjournals.org decreased in the presence of Ko143. They can be clearly identified as BCRP substrates in vesicles. Mitoxantrone and vincristine, known BCRP substrates, showed a fold uptake between 1.3 and 2, but a net uptake greater than 40 pmol/mg/min which was significantly decreased by Ko143. Similarly, cimetidine, daidzein and prazosin, also known BCRP substrates, showed a fold uptake between 1.3 and 2, but in contrast, their net uptake was below 20 pmol/mg/min and not affected by Ko143.
PhIP, sunitinib, and lamivudine, all reported BCRP substrates, showed a fold uptake below 1.3 and net uptake below the limit of quantification. They were categorized as non-BCRP substrates.
L-MDR1 Assay. In many research organizations, new molecules are routinely screened for human MDR1-mediated transport during lead optimization using cells (LLC-PK1 or MDCKII) transfected with human MDR1. The permeability results from this early MDR1 screen may provide a useful guide for selecting the correct in vitro tool (cells versus vesicles) for studies on other efflux transporters such as BCRP at a later stage in development. To test the validity of this approach, all 37 compounds that we tested for BCRP interaction were retrospectively tested in L-MDR1 cells (LLC-PK1 cells transfected with MDR1). The results are reported in detail (Supplemental Table 1 ) and are part of the summary in Table 4 .
In Table 4 , compounds have been grouped according to the results obtained from the two different BCRP methods (cells and vesiclebased). Overall, the permeability results from all compounds tested in M-BCRP and L-MDR1 assays show a good alignment. Compounds that were significantly permeable in L-MDR1 cells were also permeable (and thus suitable) in the M-BCRP cell-based assay, except for doxorubicin, which had a measurable permeability in L-MDR1 cells of 15 nm/s (very low) but was below the limit of detection in M-BCRP cells (Table 4) . Conversely, compounds not permeable in L-MDR1 cells were also not permeable in M-BCRP cells, except for coumestrol, which was not permeable in L-MDR1 cells.
BCRP Inhibition In Vitro Assay
The inhibition potential of 19 compounds was tested in vesicles using two different substrates-E3S and MTX-and in M-BCRP cells using PhIP as substrate. Fexofenadine, metformin, and vincristine were selected as negative controls (Xia et al., 2005) . The inhibition potential of typical model substrates, E3S and MTX, were tested on each other, and eight compounds were selected as well known BCRP inhibitors, especially Ko143 and FTC (Xia et al., 2005) . The inhibition potential of omeprazole, pantoprazole, eltrombopag, ritonavir, CsA, and elacridar was also determined to bridge the in vitro findings with the clinical observations reported in Table 1 for those respective inhibitors.
In all three systems, Ko143 was the most potent inhibitor with IC 50 values that are 10-fold lower than elacridar (Table 5 ). Xia and coworkers (2005) compared IC 50 data from vesicle-based and cellbased assays for Ko143, elacridar, zosuquidar, MK571, ritonavir ,   TABLE 2 BCRP substrate in vitro results of drugs tested in M-BCRP cells at 1 mM When P app AB could not be estimated as associated samples were below the limit of quantification, a value was calculated using the limit of detection and is indicated as "," to this value; equally, the ER is estimated to be "." to the calculated ratio. Ten more compounds were tested but failed in this high-throughput screening setup due to an apparent low permeability (all samples below the limit of detection, mostly corresponding to an average P appi , 15 nm/s): doxorubicin, E3S, vincristine, lamivudine, MTX, rosuvastatin, metformin, tamoxifen, nitrofurantoin, sulfasalazine. verapamil, CsA, and fexofenadine. When using E3S uptake into human BCRP vesicles, their IC 50 values are in the same range as those reported here, and the compounds ranked similarly. FTC, a mycotoxin, is one of the most potent BCRP inhibitors. Its inhibition potential on E3S and MTX in BCRP vesicles has been previously reported (0.28 mM and 0.30 mM, respectively; Chen et al., 2003; Kawahara et al., 2010) and is identical to our measured value. Our IC 50 values for imatinib, topotecan, rapamycin, eltrombopag, pantoprazole, and omeprazole are also very comparable to published results (Breedveld et al., 2004; Houghton et al., 2004; Ozvegy-Laczka et al., 2004; Gupta et al., 2006; Allred et al., 2011) . Our study is the first to report the inhibitory potential of E3S, methotrexate, vincristine, and metformin on BCRP. Overall, the three test conditions (E3S and MTX in vesicles and PhIP in cells) ranked compounds similarly. The IC 50 fold differences between E3S versus MTX in vesicles and PhIP in M-BCRP cells versus MTX in vesicles are reported in the last columns of Table 5 . There were four main outliers: topotecan, MK571, E3S, and eltrombopag. Topotecan and E3S inhibited MTX uptake into BCRP vesicles, but no inhibition was detected in M-BCRP cells when tested up to the highest soluble concentration in buffer. The potency of MK571 on MTX uptake by BCRP vesicles was 21-fold higher than on E3S uptake and 478-fold higher than on PhIP transcellular transport in M-BCRP cells. Eltrombopag was 12-fold more potent in vesicles compared with cell-based assay.
Discussion New Chemical Entities as BCRP Substrate
Why and When to Test for BCRP Substrate Property. The evidence for the clinical importance of BCRP can be seen as inconsistent and is often confounded by the involvement of multiple elimination pathways as in the clinical DDI between topotecan and elacridar ( Table 1 ). The basis of the association with BCRP over MDR1 is linked to a study in Mdr1 knockout mice, and that topotecan is described as a low affinity MDR1 substrate (Jonker et al., 2000; Kruijtzer et al., 2002) . However, in vitro data show that topotecan is a human MDR1 substrate with an ER (.4.2; Supplemental Table 1) comparable to BCRP (.6.4; Table 2), under identical experimental conditions. Moreover, although elacridar is a potent BCRP inhibitor (0.15 mM; Table 5 ), it is six times more potent against MDR1 (0.025 mM; Poirier et al., 2014) . Thus, there is reasonable evidence to suggest that the mechanism of the DDI between topotecan and elacridar is not purely mediated by BCRP, but is also linked to inhibition of MDR1. It is also worth noting that elacridar is not a marketed drug, and therefore the practical risk of a DDI with elacridar is negligible.
A significant amount of discordance is apparent when comparing the observations in Bcrp knockout mice with that of clinical findings, the most significant of which is for sulfasalazine ( Table 1 ). The fold effect on sulfasalazine exposure observed in knockout mice (111-fold AUC) does not translate to humans: sulfasalazine PK was not affected in individuals with impaired BCRP function, nor when coadministered with pantoprazole. However, in a recent clinical study, curcumin, an in vitro inhibitor of BCRP as well as aldose reductases and several drugmetabolizing enzymes, increased sulfasalazine AUC by 3-fold (Du et al., 2006; Volak et al., 2008; Kusuhara et al., 2012) . After oral administration, sulfasalazine is metabolized by bacterial azoreductases in the lumen of the colon and rectum (Yamasaki et al., 2008) . It might therefore be a possibility that the mechanism of the sulfasalazine/ curcumin interaction is not only an inhibition of BCRP but also an inhibition of the bacterial degradation of sulfasalazine in the intestine. This would also explain the lack of interaction seen between pantoprazole and sulfasalazine mentioned earlier.
Furthermore, methotrexate and rosuvastatin are clinical victim drugs that are associated with OAT-and OATP-mediated DDIs, respectively. Therefore, BCRP inhibition alone cannot be responsible dmd.aspetjournals.org for these DDIs, particularly in cases where the precipitant is CsA, a potent and promiscuous inhibitor of multiple metabolic enzymes and transport proteins. Both the FDA and EMA also acknowledge that a highly soluble and highly permeable drug may be exempt from MDR1 and BCRP testing in vivo. Most drugs whose PK is altered in BCRP pharmacogenetic studies indeed have a low permeability and a low bioavailability.
Based on the aforementioned findings, we propose not to apply a systematic evaluation of BCRP substrate properties, but rather to use a more case-by-case strategy that is based on physicochemical and PK properties of the test compound. Hence, BCRP substrate properties should be evaluated for compounds ( Fig. 1) with low permeability and low bioavailability, and where other more common interactions have been excluded from effect on absorption and/or brain disposition (e.g., MDR1 substrate), and for drugs with a low therapeutic window.
How to Test for BCRP Substrate Property. Choice of in vitro system. All permeable molecules, previously described as BCRP substrates, could be correctly categorized using M-BCRP cells as an experimental system (Table 4) . However, certain compounds were not permeable and therefore not suited for testing in the cell-based assay. There was a high rate of false negatives observed with the vesicles (40%). Initial cell-based screening assays (e.g., L-MDR1) are predictive of the passive permeability in a cellular system, and could be easily used as a selection criterion to choose between cell-based and vesicle-based assays for subsequent experiments (Fig. 1) . Given the higher risk of false negatives in vesicles, cell-based assays should remain the first choice if the drug shows acceptable permeability in cells.
Cutoff criteria. The regulatory agencies provide cutoff criteria to identify BCRP substrates in a cell-based assay (ER $ 2), although other thresholds would be acceptable, based on prior experience with the cell system used. Tables 2 and 3 clearly indicate that all compounds, previously known as BCRP substrates, showed ER $ 2 and nonsubstrate , 2. This threshold seems appropriate for the M-BCRP used under our experimental conditions. Care has to be taken to exclude false positives by including parental cells and selective inhibitors.
Establishment of a vesicle-based assay cutoff is more challenging, and must be based on a consistent and significant number of compounds tested under the same conditions. The results as presented in Table 3 indicate that a threshold of 2 in the fold uptake can clearly discriminate substrates (Fig. 1) . However, a number of recognized BCRP substrates presented a fold uptake between 1.3 and 2.0 (thus being false negatives) yet had a significant net uptake (above 30 pmol/ mg/min). It is therefore more appropriate to consider the fold uptake with a reduced threshold of 1.3, in combination with a net uptake above 30 pmol/mg/min and sensitivity to inhibition by Ko143. When applying these latter criteria, the false-negative rate was decreased (from 53% to 40%) without increasing the false-positive rate.
New Chemical Entities as BCRP Inhibitors
Why and When to Test for BCRP Inhibition Properties. In the previous section, we have discussed that all current clinical evidence associated with BCRP is ambiguous in its interpretation. In addition, should a BCRP-specific substrate/inhibitor be identified, the clinical relevance is as yet unclear. Therefore, as a further refinement to the current regulatory recommendations, our proposal is to delay the assessment of BCRP inhibition until late-stage development (i.e., phases III, IV, before filing, or even post approval) where it is still not anticipated to impact greatly on any DDI risk, but serves only to fulfill the DDI information package for completeness and regulatory compliance. However, given the previous discussion on the limited BCRP-mediated DDI evidence, the results should always be put into context of other potential and more relevant mechanisms.
How to Test for BCRP Inhibition Properties. Choice of in vitro system. BCRP inhibition has already been described as being substrate-dependent (Muenster et al., 2008; Giri et al., 2009) . In vesicles, MK571 was 21-fold more potent on MTX than on E3S (Table 5 ). The observed fold difference between IC 50 obtained using MTX in vesicles and PhIP in M-BCRP cells may also be partly due to substrate dependency, and not just because of the difference in the in vitro tool. E3S, MK571, eltrombopag, and topotecan have limited permeability in the transcellular system used in this study, and are therefore unable to reach the BCRP binding site in that system, hence the important shift in IC 50 estimated using vesicles or M-BCRP. The situation might be different if other transcellular systems are used, such as Caco2 cells or double-transfected cells, if the respective uptake transporters for the test substrate are expressed. Permeability of both substrate and inhibitor should be fundamental in (Ellens et al., 2013; Poirier et al., 2014) . It can be partly explained by the lack of clinical interactions that are clearly linked to BCRP. a ER in M-BCRP $2 significantly different in MDCKII but insensitive to Ko143 (1 mM). b ER in M-BCRP $2 but equivalent in MDCKII and insensitive to Ko143 (1 mM).
Using the lowest BCRP IC 50 from Table 2 ). The pantoprazole/sulfasalazine coadministration would have been marked as a potential DDI ([I 2 ]/ IC 50 = 38, [I 1 ]/IC 50 = 0.6), whereas no significant effect was observed (Adkison et al., 2010) .
General Conclusion
If a new chemical entity (NCE) is to be tested for BCRP substrate or inhibition properties, a careful selection of assay system is necessary to circumvent certain limitations that are inherent to each method and to avoid false readouts. The cell-based and the vesicle-based assays each offer advantages and should be selected based on physicochemical properties of the NCE. Therefore a thorough understanding of the limitations of both tools is needed for their optimal use. Similar to other transport proteins, substrate-dependent inhibition has been reported for BCRP. This could be due to either differential binding to one or multiple binding site(s) or, in the case of the cellular assay, involvement of other transporters modulating the intracellular concentration available at the binding site of BCRP. Further studies are needed to assess these properties of BCRP. Inhibition potency in such cases is mostly dependent on the substrate used in vitro.
Why and when a NCE should be tested for BCRP substrate or inhibition property is a matter of debate. Clinical examples are rare, and in cases where BCRP is involved, other transporters or metabolizing enzymes might also contribute to the interaction. We propose to place BCRP assessment as a second-line evaluation, testing first for drug transporters and metabolic enzymes for which relevant clinical examples of DDIs are more frequent and better defined. For those mechanisms, the in vitro results can be put into perspective concerning in vivo studies, using a number of clinically reported interactions to calibrate the in vitro assays. BCRP evaluation would then remain occasional: for low permeable, low bioavailable drugs, specifically when other more common processes do not allow a mechanistic understanding of unexpected absorption and/or brain disposition, and for drugs with a low therapeutic window.
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